688382 益方生物
已收盘 03-09 15:00:01
资讯
新帖
简况
3月6日益方生物涨7.11%，长城医药产业精选混合发起式A基金重仓该股
中金财经 · 03-06
3月6日益方生物涨7.11%，长城医药产业精选混合发起式A基金重仓该股
益方生物赴港上市 商业化稳定性待考
经济参考报 · 03-04
益方生物赴港上市 商业化稳定性待考
股市必读：益方生物（688382）今年截至3月3日累计跌幅已超25%
证券之星 · 03-04
股市必读：益方生物（688382）今年截至3月3日累计跌幅已超25%
每周股票复盘：益方生物（688382）净利亏损3.168亿元
证券之星 · 03-01
每周股票复盘：益方生物（688382）净利亏损3.168亿元
益方生物发布2025年度业绩快报，亏损3.168亿元
证券之星 · 02-26
益方生物发布2025年度业绩快报，亏损3.168亿元
益方生物（688382）披露调整募投项目内部投资结构公告，2月24日股价下跌1.32%
证券之星 · 02-24
益方生物（688382）披露调整募投项目内部投资结构公告，2月24日股价下跌1.32%
益方生物-U(688382.SH）赴港上市新进展：证监会要求补充三项材料
中金财经 · 02-09
益方生物-U(688382.SH）赴港上市新进展：证监会要求补充三项材料
2月2日益方生物跌9.00%，长城医药产业精选混合发起式A基金重仓该股
证券之星 · 02-02
2月2日益方生物跌9.00%，长城医药产业精选混合发起式A基金重仓该股
每周股票复盘：益方生物（688382）2025年预亏2.92亿
证券之星 · 02-01
每周股票复盘：益方生物（688382）2025年预亏2.92亿
【机构调研记录】嘉实基金调研盛美上海、益方生物
证券之星 · 01-30
【机构调研记录】嘉实基金调研盛美上海、益方生物
【私募调研记录】毅木资产调研益方生物
证券之星 · 01-30
【私募调研记录】毅木资产调研益方生物
【私募调研记录】丹羿投资调研阿拉丁、益方生物
证券之星 · 01-30
【私募调研记录】丹羿投资调研阿拉丁、益方生物
益方生物（688382）披露2025年年度业绩预亏公告，1月29日股价上涨1.51%
证券之星 · 01-29
益方生物（688382）披露2025年年度业绩预亏公告，1月29日股价上涨1.51%
益方生物(688382.SH)发预亏，预计2025年度净亏损2.92亿元
智通财经 · 01-29
益方生物(688382.SH)发预亏，预计2025年度净亏损2.92亿元
益方生物（688382）1.61亿股限售股将于1月26日解禁，占总股本27.79%
证券之星 · 01-26
益方生物（688382）1.61亿股限售股将于1月26日解禁，占总股本27.79%
每周股票复盘：益方生物（688382）部分限售股将上市流通
证券之星 · 01-18
每周股票复盘：益方生物（688382）部分限售股将上市流通
益方生物（688382）披露首次公开发行部分限售股上市流通公告，1月16日股价上涨0.9%
证券之星 · 01-16
益方生物（688382）披露首次公开发行部分限售股上市流通公告，1月16日股价上涨0.9%
益方生物冲刺港股：9个月亏损1.8亿 王耀林控制19%股权
雷递网 · 01-16
益方生物冲刺港股：9个月亏损1.8亿 王耀林控制19%股权
1月15日益方生物跌5.89%，汇添富医疗服务灵活配置混合A基金重仓该股
证券之星 · 01-15
1月15日益方生物跌5.89%，汇添富医疗服务灵活配置混合A基金重仓该股
每周股票复盘：益方生物（688382）递交H股上市申请
证券之星 · 01-11
每周股票复盘：益方生物（688382）递交H股上市申请
加载更多
公司概况
公司名称：
益方生物科技(上海)股份有限公司
所属行业：
医药制造业
上市日期：
2022-07-25
主营业务：
益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是对外授权产品贝福替尼、对外授权产品格索雷塞、临床试验阶段产品Taragarestrant、临床试验阶段产品D-0120、临床试验阶段产品D-2570。
发行价格：
18.12
{"stockData":{"symbol":"688382","market":"SH","secType":"STK","nameCN":"益方生物","latestPrice":21.56,"timestamp":1773039601000,"preClose":21.39,"halted":0,"volume":18995258,"delay":0,"changeRate":0.0079,"floatShares":578000000,"shares":578000000,"eps":-0.2011,"marketStatus":"已收盘","change":0.17,"latestTime":"03-09 15:00:01","open":21.15,"high":21.85,"low":20.75,"amount":406000000,"amplitude":0.0514,"askPrice":21.57,"askSize":115,"bidPrice":21.56,"bidSize":48,"shortable":0,"etf":0,"ttmEps":-0.2011,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773106200000},"marketStatusCode":5,"adr":0,"adjPreClose":21.39,"symbolType":"stock_kcb","openAndCloseTimeList":[[1773019800000,1773027000000],[1773032400000,1773039600000]],"highLimit":23.53,"lowLimit":19.25,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":578348491,"isCdr":false,"pbRate":7.49,"roa":"--","roe":"--","epsLYR":-0.4167,"committee":0.12938,"marketValue":12469000000,"turnoverRate":0.0328,"status":0,"afterMarket":{"amount":0,"volume":0,"close":21.56,"buyVolume":0,"sellVolume":0,"time":1773041637558,"indexStatus":"已收盘 03-09 15:30:00","preClose":21.39},"floatMarketCap":12469000000},"requestUrl":"/m/hq/s/688382","defaultTab":"news","newsList":[{"id":"2617683786","title":"3月6日益方生物涨7.11%，长城医药产业精选混合发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617683786","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617683786?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:34","pubTimestamp":1772786058,"startTime":"0","endTime":"0","summary":"证券之星消息，3月6日益方生物涨7.11%，收盘报21.39元，换手率3.52%，成交量20.36万手，成交额4.32亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共70家，其中持有数量最多的公募基金为长城基金的长城医药产业精选混合发起式A。长城医药产业精选混合发起式A目前规模为3.87亿元，最新净值1.5057，较上一交易日上涨2.18%，近一年上涨33.2%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/06/20260306506468.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/06/20260306506468.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260306/32049957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2616500303","title":"益方生物赴港上市 商业化稳定性待考","url":"https://stock-news.laohu8.com/highlight/detail?id=2616500303","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616500303?lang=zh_cn&edition=full","pubTime":"2026-03-04 07:59","pubTimestamp":1772582340,"startTime":"0","endTime":"0","summary":"益方生物（688382.SH）近日发布公告，公司已向香港联合交易所有限公司（以下简称“香港联交所”）递交发行H股股票并在香港联交所主板挂牌上市的申请。结合益方生物近年来的业绩表现和账面资 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20260304/c675054148.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260304/c675054148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2616373343","title":"股市必读：益方生物（688382）今年截至3月3日累计跌幅已超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616373343","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616373343?lang=zh_cn&edition=full","pubTime":"2026-03-04 02:22","pubTimestamp":1772562133,"startTime":"0","endTime":"0","summary":"截至2026年3月3日收盘，益方生物报收于19.93元，下跌4.69%，换手率2.54%，成交量14.72万手，成交额2.98亿元。来自交易信息汇总：近90天内3家机构对益方生物给出评级，其中买入评级2家，增持评级1家，机构目标均价为49.25元。交易信息汇总股价提醒3月3日益方生物收盘报19.93元，跌4.69%，当日成交1471.79万元。该股已连续2日下跌，当年累计跌幅26.83%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400001315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2616845883","title":"每周股票复盘：益方生物（688382）净利亏损3.168亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616845883","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616845883?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:30","pubTimestamp":1772303433,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，益方生物报收于21.34元，较上周的22.01元下跌3.04%。本周，益方生物2月24日盘中最高价报22.33元。本周关注点业绩披露要点：益方生物2025年归属净利润亏损3.168亿元，同比减少31.9%。益方生物科技（上海）股份有限公司预计2025年度实现营业收入3,732.53万元，较上年同期下降77.89%；归属于母公司所有者的净利润为-31,683.84万元，亏损较上年同期扩大。出席会议股东共221人，代表有表决权股份总数218,902,289股，占公司总表决权数的37.8495%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2614301470","title":"益方生物发布2025年度业绩快报，亏损3.168亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614301470","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614301470?lang=zh_cn&edition=full","pubTime":"2026-02-26 18:21","pubTimestamp":1772101283,"startTime":"0","endTime":"0","summary":"证券之星消息，益方生物近日即将发布2025年年报，根据2月26日发布的业绩快报，归属净利润亏损3.168亿元，同比减少31.9%。基于 2025 年的整体研发进展，公司在报告期内持续保持了高强度的研发投入，公司本期技术授权和技术合作收入尚无法覆盖各项成本及费用，预计 2025年度将继续出现亏损的情况，但公司主营业务、核心竞争力没有发生重大不利变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600030181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2613879478","title":"益方生物（688382）披露调整募投项目内部投资结构公告，2月24日股价下跌1.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613879478","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613879478?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:01","pubTimestamp":1771927270,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，益方生物报收于21.72元，较前一交易日下跌1.32%，最新总市值为125.62亿元。该股当日开盘22.21元，最高22.33元，最低21.61元，成交额达2.05亿元，换手率为1.63%。近日，益方生物披露《2026年第一次临时股东会会议资料》公告。公司拟调整募投项目“新药研发项目”内部投资结构，新增子项目“YF550”，并调整各子项目间募集资金分配，总投资金额不变。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400034278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2610028655","title":"益方生物-U(688382.SH）赴港上市新进展：证监会要求补充三项材料","url":"https://stock-news.laohu8.com/highlight/detail?id=2610028655","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610028655?lang=zh_cn&edition=full","pubTime":"2026-02-09 10:30","pubTimestamp":1770604201,"startTime":"0","endTime":"0","summary":"览富财经网讯：2月6日，中国证监会公布最新一期《境外发行上市备案补充材料要求》，本周国际司共对4家企业出具补充材料要求，其中对在2026年1月1日，向港交所主板递交上市申请书的益方生物科技 股份有限公司，证监会要求其需补充说明三项事项且需律师核查并出具明确的法律意见。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260209/32006805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2608185132","title":"2月2日益方生物跌9.00%，长城医药产业精选混合发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608185132","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608185132?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:44","pubTimestamp":1770021840,"startTime":"0","endTime":"0","summary":"根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共70家，其中持有数量最多的公募基金为长城基金的长城医药产业精选混合发起式A。长城医药产业精选混合发起式A目前规模为3.87亿元，最新净值1.6587，较上一交易日下跌0.32%，近一年上涨77.44%。梁福睿在任的基金产品包括:长城港股医疗保健精选混合发起A，管理时间为2025年8月20日至今，期间收益率为-17.11%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200023480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2608724920","title":"每周股票复盘：益方生物（688382）2025年预亏2.92亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2608724920","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608724920?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:32","pubTimestamp":1769880732,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，益方生物报收于25.56元，较上周的26.45元下跌3.36%。本周，益方生物1月30日盘中最高价报27.2元。来自公司公告汇总：公司2025年度营收预计为3,724.52万元，扣除后仍低于1亿元。业绩披露要点益方生物发布业绩预告，预计2025年全年营业收入3,724.52万元。预计2025年全年归属净利润亏损约2.92亿元。公司公告汇总益方生物预计2025年度实现利润总额-29,182.21万元，归属于母公司所有者的净利润-29,219.53万元，扣除非经常性损益后净利润为-30,440.75万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2607050030","title":"【机构调研记录】嘉实基金调研盛美上海、益方生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2607050030","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607050030?lang=zh_cn&edition=full","pubTime":"2026-01-30 08:11","pubTimestamp":1769731902,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及1月29日披露的机构调研信息，嘉实基金近期对2家上市公司进行了调研，相关名单如下：1）盛美上海 调研纪要：公司预计2026年海外市场开拓速度相对2025年会加速。嘉实基金成立于1999年，截至目前，资产管理规模11784.42亿元，排名7/212；资产管理规模7594.66亿元，排名6/212；管理公募基金数635只，排名10/212；旗下公募基金经理97人，排名8/212。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000007047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688382","688082","BK0239"],"gpt_icon":0},{"id":"2607205007","title":"【私募调研记录】毅木资产调研益方生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2607205007","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607205007?lang=zh_cn&edition=full","pubTime":"2026-01-30 08:11","pubTimestamp":1769731892,"startTime":"0","endTime":"0","summary":"根据市场公开信息及1月29日披露的机构调研信息，知名私募毅木资产近期对1家上市公司进行了调研，相关名单如下：1）益方生物 调研纪要：公司控股股东对公司未来发展充满信心，本次限售股解禁为正常流通安排，非减持信号，目前无法减持，亦无减持计划。公司投研团队在权益类投资领域拥有丰富的投资经验，通过有效的风险控制，把握资本市场相对确定的投资机会，实现资产穿越牛熊的复合增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026013000007025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2607050042","title":"【私募调研记录】丹羿投资调研阿拉丁、益方生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2607050042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607050042?lang=zh_cn&edition=full","pubTime":"2026-01-30 08:11","pubTimestamp":1769731889,"startTime":"0","endTime":"0","summary":"根据市场公开信息及1月29日披露的机构调研信息，知名私募丹羿投资近期对2家上市公司进行了调研，相关名单如下：1）阿拉丁 调研纪要：工业客户在供应商选择上最看重稳定性，包括供货稳定，产品质量稳定、批间差小、参数波动小，同时供货量需要匹配客户产能释放节奏。2）益方生物 调研纪要：公司控股股东对公司未来发展充满信心，本次限售股解禁为正常流通安排，非减持信号，目前无法减持，亦无减持计划。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026013000007016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688179","688382","BK0239"],"gpt_icon":0},{"id":"2607033286","title":"益方生物（688382）披露2025年年度业绩预亏公告，1月29日股价上涨1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607033286","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607033286?lang=zh_cn&edition=full","pubTime":"2026-01-29 22:19","pubTimestamp":1769696359,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，益方生物报收于25.55元，较前一交易日上涨1.51%，最新总市值为147.77亿元。该股当日开盘25.17元，最高25.98元，最低24.65元，成交额达2.91亿元，换手率为1.98%。近日，益方生物发布《2025年年度业绩预亏公告》。公告同时指出，公司主营业务和核心竞争力未发生重大不利变化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900043438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2607108798","title":"益方生物(688382.SH)发预亏，预计2025年度净亏损2.92亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607108798","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607108798?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:55","pubTimestamp":1769691328,"startTime":"0","endTime":"0","summary":"智通财经APP讯，益方生物 发布2025年年度业绩预亏公告，预计2025年度实现归属于母公司所有者净亏损2.92亿元。2025年度，公司业绩变化主要受到研发投入强度与营收构成的共同影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399386.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2606619032","title":"益方生物（688382）1.61亿股限售股将于1月26日解禁，占总股本27.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606619032","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606619032?lang=zh_cn&edition=full","pubTime":"2026-01-26 08:01","pubTimestamp":1769385707,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，益方生物于1月26日将有1.61亿股限售股份解禁，为公司追加承诺限售股份上市流通，占公司总股本27.79%。最近一年内，该股累计解禁1631.47万股，占总股本的2.82%。益方生物主营业务：创新药物的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600001954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2604923073","title":"每周股票复盘：益方生物（688382）部分限售股将上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2604923073","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604923073?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:33","pubTimestamp":1768678387,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，益方生物报收于30.14元，较上周的33.4元下跌9.76%。公司公告汇总益方生物科技（上海）股份有限公司首次公开发行部分限售股将于2026年1月26日上市流通，本次上市流通数量为160,715,196股，占公司总股本的27.79%。公司总股本因限制性股票归属由575,000,000股变更为578,348,491股。相关股东均严格履行股份锁定承诺，保荐人对本次限售股上市流通无异议。限售期为自公司上市之日起42个月。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2603257994","title":"益方生物（688382）披露首次公开发行部分限售股上市流通公告，1月16日股价上涨0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603257994","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603257994?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:39","pubTimestamp":1768574350,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，益方生物报收于30.14元，较前一交易日上涨0.9%，最新总市值为174.31亿元。公司近日发布公告称，首次公开发行部分限售股将于2026年1月26日起上市流通，涉及股东5名，限售股总数160,715,196股，占公司总股本27.79%。限售期为自公司上市之日起42个月。本次上市后，上述股东所持相关限售股全部解除限售。公司总股本因股权激励归属已由575,000,000股增至578,348,491股。保荐人中信证券对本次限售股上市流通无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600041355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2603995618","title":"益方生物冲刺港股：9个月亏损1.8亿 王耀林控制19%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2603995618","media":"雷递网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603995618?lang=zh_cn&edition=full","pubTime":"2026-01-16 20:30","pubTimestamp":1768566641,"startTime":"0","endTime":"0","summary":"益方生物科技（上海）股份有限公司（简称：“益方生物”）日前递交招股书，准备在港交所上市。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260116/6390419223720368045154107.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260116/6390419223720368045154107.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n32398/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2603671072","title":"1月15日益方生物跌5.89%，汇添富医疗服务灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603671072","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603671072?lang=zh_cn&edition=full","pubTime":"2026-01-15 15:35","pubTimestamp":1768462547,"startTime":"0","endTime":"0","summary":"证券之星消息，1月15日益方生物跌5.89%，收盘报29.87元，换手率4.42%，成交量18.44万手，成交额5.61亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共88家，其中持有数量最多的公募基金为汇添富基金的汇添富医疗服务灵活配置混合A。汇添富医疗服务灵活配置混合A目前规模为30.61亿元，最新净值1.869，较上一交易日下跌1.58%，近一年上涨57.72%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500019897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2602533265","title":"每周股票复盘：益方生物（688382）递交H股上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2602533265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602533265?lang=zh_cn&edition=full","pubTime":"2026-01-11 01:59","pubTimestamp":1768067947,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，益方生物报收于33.4元，较上周的27.24元上涨22.61%。本周，益方生物1月9日盘中最高价报33.59元。本周关注点公司公告汇总：益方生物已向港交所递交H股发行上市申请，并刊发申请资料。本次发行需获中国证监会、香港证监会及港交所等监管机构批准，存在不确定性。益方生物董事会薪酬与考核委员会对2025年限制性股票激励计划激励对象名单进行了审核，并于2025年12月23日至2026年1月6日完成公司内部公示。公示期间未收到异议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773101102508,"stockEarnings":[{"period":"1week","weight":0.0311},{"period":"1month","weight":-0.0739},{"period":"3month","weight":-0.2352},{"period":"6month","weight":-0.3854},{"period":"1year","weight":0.1846},{"period":"ytd","weight":-0.2085}],"compareEarnings":[{"period":"1week","weight":-0.0206},{"period":"1month","weight":0.0076},{"period":"3month","weight":0.0479},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.2147},{"period":"ytd","weight":0.0322}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"益方生物科技(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12352人(较上一季度增加26.17%)","perCapita":"46822股","listingDate":"2022-07-25","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路67弄4号210室","registeredCapital":"57834万元","survey":" 益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是对外授权产品贝福替尼、对外授权产品格索雷塞、临床试验阶段产品Taragarestrant、临床试验阶段产品D-0120、临床试验阶段产品D-2570。","listedPrice":18.12},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"益方生物(688382)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供益方生物(688382)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"益方生物,688382,益方生物股票,益方生物股票老虎,益方生物股票老虎国际,益方生物行情,益方生物股票行情,益方生物股价,益方生物股市,益方生物股票价格,益方生物股票交易,益方生物股票购买,益方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"益方生物(688382)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供益方生物(688382)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}